119 related articles for article (PubMed ID: 26460822)
1. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings.
Hoyt D; Hughes J; Liu J; Ayyad H
Radiol Case Rep; 2024 Jun; 19(6):2168-2182. PubMed ID: 38515768
[TBL] [Abstract][Full Text] [Related]
3. Checking whether there is an increased risk of post-transplant lymphoproliferative disorder and other cancers with specific modern immunosuppression regimens in renal transplantation: protocol for a network meta-analysis of randomized and observational studies.
Hutton B; Joseph L; Yazdi F; Tetzlaff J; Hersi M; Kokolo M; Fergusson N; Bennett A; Buenaventura C; Fergusson D; Tricco A; Strauss S; Moher D; Knoll G
Syst Rev; 2014 Feb; 3():16. PubMed ID: 24559430
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and Management of CKD in the Nonkidney Solid Organ Transplant Recipient.
Warburton KM; Doyle AM
Clin J Am Soc Nephrol; 2018 Apr; 13(4):652-654. PubMed ID: 29326305
[No Abstract] [Full Text] [Related]
5. Hairy cell leukemia in kidney transplantation: lesson from a rare disorder.
Vinante F; Tomei P; Zaza G; Zamò A; Lupo A
Exp Hematol Oncol; 2013; 2():22. PubMed ID: 23927433
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant lymphoproliferative disorder after kidney transplantation with organ-specific disease.
Banaszkiewicz M; Okoń K; Popiela T; Buziak-Bereza M; Krzanowski M; Krzanowska K
Pol Arch Intern Med; 2024 Mar; ():. PubMed ID: 38488123
[No Abstract] [Full Text] [Related]
7. [EBV-positive central nervous system lymphoproliferative disease associated with immunosuppression after organ transplantation: Long-term remission without chemotherapy].
Gavrilina OA; Troitskaya VV; Zvonkov EE; Parovichnikova EN; Galstyan GM; Biryukova LS; Nesterenko IV; Kovrigina AM; Bazhenov AV; Savchenko VG; Savchenko VG
Ter Arkh; 2017; 89(7):69-75. PubMed ID: 28766544
[TBL] [Abstract][Full Text] [Related]
8. Growth Transformation of B Cells by Epstein-Barr Virus Requires
Sugimoto A; Watanabe T; Matsuoka K; Okuno Y; Yanagi Y; Narita Y; Mabuchi S; Nobusue H; Sugihara E; Hirayama M; Ide T; Onouchi T; Sato Y; Kanda T; Saya H; Iwatani Y; Kimura H; Murata T
Microbiol Spectr; 2023 Aug; 11(4):e0044023. PubMed ID: 37409959
[TBL] [Abstract][Full Text] [Related]
9. Systemic Sclerosis Association with Malignancy.
Lepri G; Catalano M; Bellando-Randone S; Pillozzi S; Giommoni E; Giorgione R; Botteri C; Matucci-Cerinic M; Antonuzzo L; Guiducci S
Clin Rev Allergy Immunol; 2022 Dec; 63(3):398-416. PubMed ID: 36121543
[TBL] [Abstract][Full Text] [Related]
10. CNS Post-Transplant Lymphoproliferative Disorder in a Heart Recipient: A Case Report.
Amin A; Chenaghlou M; Zare E; Naderi N; Taghavi S
Int J Organ Transplant Med; 2021; 12(2):46-49. PubMed ID: 34987738
[TBL] [Abstract][Full Text] [Related]
11. Primary CNS lymphoma in scleroderma: a case series.
Robinett DM; Hummers LK; Morris M; Duffield AS; Shah AA
J Scleroderma Relat Disord; 2021 Jun; 6(2):214-219. PubMed ID: 34350365
[TBL] [Abstract][Full Text] [Related]
12. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic granulomatosis with polyangiitis (EGPA) on remission with a new neuropathy: a rare case of mycophenolate induced primary CNS lymphoproliferative disease.
Shrestha P; Garrahy I; Rahimian S
J Community Hosp Intern Med Perspect; 2020 Oct; 10(6):600-603. PubMed ID: 33194139
[TBL] [Abstract][Full Text] [Related]
14. Cancer and Scleroderma.
Weeding E; Casciola-Rosen L; Shah AA
Rheum Dis Clin North Am; 2020 Aug; 46(3):551-564. PubMed ID: 32631603
[TBL] [Abstract][Full Text] [Related]
15. Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders.
Watanabe M; Kanda J; Hishizawa M; Nishikori M; Kondo T; Yamashita K; Takaori-Kondo A
Ann Hematol; 2020 Jul; 99(7):1565-1573. PubMed ID: 32436013
[TBL] [Abstract][Full Text] [Related]
16. Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.
Ichikawa T; Shimojima Y; Kishida D; Kaneko T; Sekijima Y
Rheumatol Int; 2021 May; 41(5):1009-1017. PubMed ID: 32253501
[TBL] [Abstract][Full Text] [Related]
17. The relationships between cancer and autoimmune rheumatic diseases.
Cappelli LC; Shah AA
Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101472. PubMed ID: 32029389
[TBL] [Abstract][Full Text] [Related]
18. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.
Kaulen LD; Galluzzo D; Hui P; Barbiero F; Karschnia P; Huttner A; Fulbright R; Baehring JM
J Neurooncol; 2019 Aug; 144(1):107-115. PubMed ID: 31190317
[TBL] [Abstract][Full Text] [Related]
19. A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature.
Velvet AJJ; Bhutani S; Papachristos S; Dwivedi R; Picton M; Augustine T; Morton M
Oncotarget; 2019 Jan; 10(4):437-448. PubMed ID: 30728897
[TBL] [Abstract][Full Text] [Related]
20. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?
Natkunam Y; Gratzinger D; Chadburn A; Goodlad JR; Chan JKC; Said J; Jaffe ES; de Jong D
Blood; 2018 Nov; 132(18):1871-1878. PubMed ID: 30082493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
